Bispyridinium cyclophanes: Novel templates for human choline kinase inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 17, 2003, Pages 3754-3757

  Conejo García, Ana ^a   Campos, Joaquín M ^a   Sánchez Martín, Rosario M ^a   Gallo, Miguel Á ^a   Espinosa, Antonio ^a  

^a Facultad de Farmacia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4,8 DIAZA 3,9 DIPYRIDINA 1,6 DIBENZENACYCLODECAPHAN 3,9 BIS(ILIUM) DIBROMIDE; BISPYRIDINIUM CYCLOPHANE DERIVATIVE; CHOLINE KINASE; CHOLINE KINASE INHIBITOR; CYCLOPHANE DERIVATIVE; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DILUTION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; REACTION ANALYSIS; REACTION TIME; TEMPERATURE DEPENDENCE;

ANTINEOPLASTIC AGENTS; CHOLINE KINASE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; PYRIDINES; PYRIDINIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0041565216     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030792i     Document Type: Article

References (23)

1. Barbacid, M. Ras genes. Annu. Rev. Biochem. 1987, 56, 779-827.
2. Tsai, M.; Yu, C.; Stacey, D. The effect of GTPase activating protein upon ras is inhibited by mitogenically responsive lipids. Science 1989, 243, 522-526.
3. Yu, C.; Tsay, M.; Stacey, D. Serum stimulation of NIH 3T3 cells induces the production of lipids able to inhibit GTPase activating protein activity. Mol. Cell. Biol. 1990, 10, 6683-6689.
4. Lacal, J. C.; Carnero, A. Regulation of ras proteins and their involvement in signal transduction pathways. Oncol. Rep. 1994, 1, 677-693.
5. Nakagami, K.; Uchida, T.; Ohwada, S.; Koibuchi, Y.; Suda, Y.; Sekine, T. ; Morishita, Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res. 1999, 90, 419-424.
6. Ruiz-Cabello, J.; Cohen, J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992, 5, 226-233.
7. de Certaines, J. D.; Larsen, V. A.; Podo, F.; Carinelli, G.; Briot, O.; Henriksen, O. In vivo 31P MRS of experimental tumours. NMR Biomed. 1993, 6, 345-365.
8. Smith, T. A. D.; Bush, C.; Jameson, C.; Titley, J. C.; Leach, M. O.; Wilman, D. E. V.; McCready, V. R. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed. 1993, 6, 318-323.
9. Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999, 59, 3112-3118.
10. Hernández-Alcoceba, R.; Saniger, L.; Campos, J.; Núñez, M. C.; Khaless, F.; Gallo, M. A.; Espinosa, A.; Lacal, J. C. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997, 15, 2289-2301.
11. Campos, J.; Núñez, M. C.; Rodríguez, V.; Gallo, M. Á.; Espinosa, A. QSAR of 1,1′-(1,2-ethylenebisbenzyl)bis(4-substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design. Bioorg. Med. Chem. Lett. 2000, 10, 767-770.
12. Campos, J.; Núñez, M. C.; Rodríguez, V.; Entrena, A. ; Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C.; Gallo, M. A.; Espinosa, A. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. Eur. J. Med. Chem. 2001, 36, 215-225.
13. Campos, J.; Núñez, M. C.; Sánchez, R. M.; Gómez-Vidal, J. A.; Rodríguez-González, A.; Báñez, M.; Gallo, M. A.; Lacal, J. C.; Espinosa, A. Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg. Med. Chem. 2002, 10, 2215-2231.
14. Conejo-García, A.; Campos, J.; Sánchez, R. M.; Rodríguez-González, A.; Lacal, J. C.; Gallo, M. Á.; Espinosa, A. Choline kinase inhibitory effect and antiproliferative activity of new 1,1′,1″-(benzene-1,3,5-triylmethylene)tris{4- [(disubstituted)aminolpyridinium} tribromides. Eur. J. Med. Chem. 2003, 38, 109-116.
15. Campos, J.; Núñez, M. C.; Conejo-García, A.; Sánchez-Martín, R. M.; Hernández-Alcoceba, R.; Rodríguez-González, A.; Lacal, J. C.; Gallo, M. Á.; Espinosa, A. QSAR-derived choline kinase inhibitors: How rational can antiproliferative drug design be? Curr. Med. Chem. 2003, 10, 1241-1253.
16. Surrey, A. R.; Cutler, R. K. The role of phenol in the reaction of 4,7-dichloroquinoline with novol diamine. J. Am. Chem. Soc. 1951, 73, 2623-2626.
17. + channel. J. Med. Chem. 2000, 43, 420-431.
18. + channel. J. Med. Chem. 2000, 43, 3478-3481.
19. Schnall, S.; Macdonald, J. S. In Manual of Oncologic Therapeutics; Macdonald, J. S., Haller, D. G., Mayer, R. J., Eds.; J. B. Lippincott Co.: Philadelphia, PA, 1995; pp 170-184.
20. Phane Nomenclature. Part I: Phane Parent Names. IUPAC Recommendations 1998. http://www.chem.qmw.ac.uk/iupac/phane.
21. Phane Nomenclature. Part II: Substitution Derivatives of Phane Parent Hydrides. IUPAC Recommendations 2001. http://www.chem.qmw.ac.uk/iupac/phane.
22. Lucas, L.; Hernández-Alcoceba, R.; Rodríguez, P.; Lacal, J. C. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene 2001, 20, 1110-1117.
23. Ramírez de Molina, A.; Peñalva, V.; Lucas, L.; Lacal, J. C. Regulation of choline kinase activity by Ras proteins involves RaI-GDS and PI3K. Oncogene 2002, 21, 937-946.